http://www.gastroendonews.com/ViewArticle.aspx?d=In%2Bthe%2BNews&d_id=187&i=May+2014&i_id=1059&a_id=27434
The body of evidence linking inflammatory bowel disease (IBD) and its treatments with an increased risk for nonmelanoma skin cancer is sufficient to support more rigorous prevention efforts, according to a recent review of the data. Although some but not all therapies for IBD are associated with an exacerbation of risk, IBD alone poses an increased likelihood for developing skin cancer and warrants a more aggressive approach toward prophylaxis.
The body of evidence linking inflammatory bowel disease (IBD) and its treatments with an increased risk for nonmelanoma skin cancer is sufficient to support more rigorous prevention efforts, according to a recent review of the data. Although some but not all therapies for IBD are associated with an exacerbation of risk, IBD alone poses an increased likelihood for developing skin cancer and warrants a more aggressive approach toward prophylaxis.
